Clinical Trials Logo

PCI clinical trials

View clinical trials related to PCI.

Filter by:
  • None
  • Page 1

NCT ID: NCT06247982 Recruiting - De Novo Stenosis Clinical Trials

Bail-Out Stenting and Target-vessel Failure After Drug Coated Balloon Coronary percutaneouS Angioplasty for de Novo Lesions

BOSS
Start date: November 6, 2023
Phase:
Study type: Observational

The goal of this observational retrospective and prospective multicentric trial is to learn about the impact of bail-out stenting (BOS) after drug coated balloon (DCB) percutaneous coronary angioplasty (PCI) in de novo coronary stenosis.The main question to answer is: - if BOS PCI leads to an higher rate of 1-year target vessel failure that DCB-only PCI. Partecipants will recieve DCB PCI in de novo coronary stenosis. Treatments they'll be given should be: - DCB-only PCI - BOS PCI Reaserchers will compare DCB-only and BOS group to see if addictive stent implantation for DCB-PCI complication is relate to an higher rate of target vessel failure. Target vessel is the primary endpoint, defined as: - cardiovascular death - target vessel myocardial infarction - clinical driven target vessel revascularization - angiographic restenosis

NCT ID: NCT04500912 Completed - Cardiac Disease Clinical Trials

Comparison of the Supraflex Cruz 60 Micron Versus the Ultimaster Tansei 80 Micron in HBR PCI Population

Start date: September 14, 2020
Phase: N/A
Study type: Interventional

The study compares the outcome of the ultrathin stent strut Supraflex Cruz stent to the thin stent strut Ultimaster Tansei stent in a PCI population at high risk for bleeding (HBR).

NCT ID: NCT04310046 Recruiting - Clinical trials for Coronary Artery Disease

Optimal Timing of Transcatheter Aortic Valve Implantation and Percutaneous Coronary Intervention - The TAVI PCI Trial

TAVI-PCI
Start date: September 30, 2020
Phase: N/A
Study type: Interventional

The primary objective of this study is to compare, in patients with severe aortic stenosis and concomitant coronary artery disease accepted for transcatheter aortic valve implantation (TAVI) and percutaneous coronary intervention (PCI) by the multidisciplinary Heart Team, the safety and efficacy of angiography-guided complete revascularization performed after (within 1-45 days) with angiography-guided complete revascularization performed before (within 1-45 days) TAVI using the Edwards SAPIEN Transcatheter Heart Valve®.

NCT ID: NCT03479840 Completed - Clinical trials for Coronary Artery Disease

Age-Dependent Impact of the SYNTAX-score on Mortality

Start date: January 1, 2013
Phase:
Study type: Observational

The SYNTAX-score has been proposed as a tool for risk stratification and guiding revascularization therapy in patients with complex coronary artery disease. There are limited data on the prognostic value of the SYNTAX-score among elderly patients. Aim of this study was to investigate whether age modifies the impact of the SYNTAX-score on all-cause mortality at 2 years after percutaneous coronary intervention (PCI).

NCT ID: NCT03424941 Active, not recruiting - Aortic Stenosis Clinical Trials

The TransCatheter Valve and Vessels Trial

TCW
Start date: May 31, 2018
Phase: N/A
Study type: Interventional

The trial objective is to investigate whether Fractional Flow Reserve (FFR)-Guided Percutaneous Coronary Intervention (PCI) and TransCatheter Aortic Valve Implantation (TAVI) strategy for treatment of multivessel disease and aortic stenosis will be non-inferior to Coronary Artery By-pass Grafting (CABG) and Surgical Aortic Valve Replacement (SAVR) for a composite primary endpoint of all-cause mortality, stroke, myocardial infarction, coronary or valve re-intervention and life-threatening or disabling bleeding at one year.

NCT ID: NCT03058627 Active, not recruiting - Clinical trials for Coronary Artery Disease

Revascularization in Patients Undergoing Transcatheter Aortic Valve Implantation

NOTION-3
Start date: September 15, 2017
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the effect of routine FFR-guided complete revascularization with PCI compared to conservative management in patients with concomitant coronary artery disease who are undergoing TAVI.

NCT ID: NCT03023020 Completed - Clinical trials for Coronary Artery Disease

Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen

MASTER DAPT
Start date: April 4, 2017
Phase: N/A
Study type: Interventional

The study compares two lengths of medication therapy (a shortened versus a prolonged dual antiplatelet therapy) in order to prevent thrombus (blood cloth) formation after the successfully treatment for coronary heart disease with a drug covered stent (metallic tube). This comparison will be done in patients who, compared to the average patient, are more likely to suffer from complications on antiplatelet therapy (bleeding). Both durations are within the current medical recommendations. The aim of this study is to help improve further standard antiplatelet duration guidelines.

NCT ID: NCT02849691 Completed - Bleeding Clinical Trials

Plasma Dipeptidyl-peptidase-4 Activities With No-reflow and Bleeding

Start date: January 2014
Phase: N/A
Study type: Observational

Dipeptidyl-peptidase-4 (DPP4) is an important regulator of incretins and inflammation, and participates in the pathophysiological process of acute myocardial infarction (AMI). However clinical data of DPP4a in AMI patients is sparse. This study was to investigate the role of plasma DPP4 activity (DPP4a) in patients with ST-segment elevation myocardial infarction (STEMI) treated with percutaneous coronary intervention (PCI). This was a analysis of consecutive patients conducted at a tertiary referral center from January 2014 to October 2015. The investigators included 747 STEMI-patients, treated with PCI from January 2013 to October 2015. Blood samples were collected immediately at admission. The patients were divided into four groups according to DPP4a quartile.

NCT ID: NCT02297971 Completed - PCI Clinical Trials

Assessment of Coagulation and Thrombocyte Function After Termination of Ticagrelor

BRILIQUE
Start date: September 2013
Phase: N/A
Study type: Observational

When ticagrelor should be discontinued prior to elective surgery is unclear. The risks of bleeding when it is continued peri-operatively have to be weighed against the risk of coronary artery thrombosis when stopped. This study aims to assess coagulation and thrombocyte function every other day in patients who are taking ticagrelor after coronary artery stents and discontinue therapy at the end of one year.